| CAS NO: | 2095432-65-6 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 523.43 |
|---|---|
| Formula | C19H18F5N5O5 |
| CAS No. | 2095432-65-6 (TFA) |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 81 mg/mL (154.74 mM) |
| Water: <1 mg/mL | |
| Ethanol: 2 mg/mL (3.82 mM) | |
| SMILES | O=C(NC1=CC=C(F)C([C@@](C2)(C)N=C(N)N(C)S2(=O)=O)=C1)C3=NC=C(F)C=C3.O=C(O)C(F)(F)F |
| Synonyms | MK-8931 TFA; SCH 900931; MK 8931 trifluoroactice acid; SCH-900931; MK8931; MK-8931-009; SCH900931 TFA |
| In Vitro | In vitro activity: Verubecestat(MK-8931) effectively reduces Aβ40 in cells with a Ki of 7.8 nM and an IC50 of 13 nM Kinase Assay: Verubecestat (MK-8931) is a beta-secretase 1/BACE1 inhibitor under investigation for the treatment of Alzheimer's Disease. |
|---|---|
| In Vivo | Verubecestat(MK-8931) dramatically lowers CSF and cortex Aβ40 in both rats and cynomolgus monkeys following a single oral dose. Due to the 20 h half-life of MK-8931 it is ideal for once-a-day dosing. |
| Animal model | Rats and cynomolgus monkeys |
| Formulation & Dosage | NA |
| References | BioDrugs. 2016 Jun;30(3):173-94; Transl Neurodegener. 2016 Jul 14;5:13. |
m.cnreagent.com